Peripheral blood analysis
| Group . | n . | WBCs, × 103/μL . | RBCs, × 106/μL . | Hematocrit, % . | Platelets, × 103/μL . | Neutrophils, % . | Lymphocytes, % . | Monocytes, % . | Eosinophils, % . | Basophils, % . | Blasts, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Wild-type | |||||||||||
| NR4A1+/+NR4A3+/+ | 4 | 5.98 ± 0.9 | 9.57 ± 0.46 | 45.11 ± 1.19 | 1164 ± 155 | 10.0 ± 1.7 | 83.9 ± 1.6 | 1.5 ± 0.3 | 2.4 ± 0.4 | 0.1 ± 0.1 | 0.97 ± 0.8 |
| Disease-free | |||||||||||
| NR4A1−/−NR4A3+/+ | 8 | 4.36 ± 1.2 | 9.93 ± 0.41 | 44.40 ± 1.10 | 1148 ± 163 | 12.3 ± 1.1 | 83.1 ± 2.7 | 1.4 ± 0.3 | 2.9 ± 0.5 | 0.2 ± 0.1 | 1.13 ± 0.6 |
| NR4A1+/+NR4A3−/− | 9 | 5.2 ± 1.1 | 9.96 ± 0.38 | 44.35 ± 1.16 | 1161 ± 160 | 13.4 ± 2.2 | 83.3 ± 1.8 | 1.2 ± 0.4 | 2.5 ± 0.6 | 0.2 ± 0.1 | 1.30 ± 0.7 |
| MDS/MPN* | |||||||||||
| NR4A1+/−NR4A3−/− | 25 | 12.75 ± 14.2 | 8.16 ± 2.54 | 37.37 ± 11.8 | 744 ± 369 | 32.0 ± 13.1 | 53.3 ± 16.5 | 3.1 ± 2.4 | 4.2 ± 3.1 | 0.4 ± 0.1 | 5.9 ± 4.6 |
| NR4A1−/−NR4A3+/− | 20 | 10.83 ± 6.71 | 8.34 ± 1.52 | 42.28 ± 7.07 | 799 ± 476 | 31.7 ± 15.4 | 51.1 ± 19.7 | 4.2 ± 3.6 | 5.5 ± 3.3 | 0.9 ± 0.3 | 6.1 ± 5.1 |
| AML† | |||||||||||
| NR4A1+/−NR4A3−/− | 3 | 23.6 ± 20.5 | 6.33 ± 3.91 | 29.37 ± 18.4 | 235 ± 266 | 23.4 ± 3.2 | 40.3 ± 7.6 | 2.1 ± 0.4 | 2.9 ± 0.4 | 0.2 ± 0.2 | 31.0 ± 7.4 |
| NR4A1−/−NR4A3+/− | 2 | 8.05 ± 1.18 | 6.50 ± 1.70 | 22.80 ± 4.20 | 114 ± 32.6 | 15.2 ± 1.4 | 48.9 ± 7.1 | 1.9 ± 0.6 | 3.6 ± 1.3 | 0.3 ± 0.3 | 30.1 ± 5.3 |
| Group . | n . | WBCs, × 103/μL . | RBCs, × 106/μL . | Hematocrit, % . | Platelets, × 103/μL . | Neutrophils, % . | Lymphocytes, % . | Monocytes, % . | Eosinophils, % . | Basophils, % . | Blasts, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Wild-type | |||||||||||
| NR4A1+/+NR4A3+/+ | 4 | 5.98 ± 0.9 | 9.57 ± 0.46 | 45.11 ± 1.19 | 1164 ± 155 | 10.0 ± 1.7 | 83.9 ± 1.6 | 1.5 ± 0.3 | 2.4 ± 0.4 | 0.1 ± 0.1 | 0.97 ± 0.8 |
| Disease-free | |||||||||||
| NR4A1−/−NR4A3+/+ | 8 | 4.36 ± 1.2 | 9.93 ± 0.41 | 44.40 ± 1.10 | 1148 ± 163 | 12.3 ± 1.1 | 83.1 ± 2.7 | 1.4 ± 0.3 | 2.9 ± 0.5 | 0.2 ± 0.1 | 1.13 ± 0.6 |
| NR4A1+/+NR4A3−/− | 9 | 5.2 ± 1.1 | 9.96 ± 0.38 | 44.35 ± 1.16 | 1161 ± 160 | 13.4 ± 2.2 | 83.3 ± 1.8 | 1.2 ± 0.4 | 2.5 ± 0.6 | 0.2 ± 0.1 | 1.30 ± 0.7 |
| MDS/MPN* | |||||||||||
| NR4A1+/−NR4A3−/− | 25 | 12.75 ± 14.2 | 8.16 ± 2.54 | 37.37 ± 11.8 | 744 ± 369 | 32.0 ± 13.1 | 53.3 ± 16.5 | 3.1 ± 2.4 | 4.2 ± 3.1 | 0.4 ± 0.1 | 5.9 ± 4.6 |
| NR4A1−/−NR4A3+/− | 20 | 10.83 ± 6.71 | 8.34 ± 1.52 | 42.28 ± 7.07 | 799 ± 476 | 31.7 ± 15.4 | 51.1 ± 19.7 | 4.2 ± 3.6 | 5.5 ± 3.3 | 0.9 ± 0.3 | 6.1 ± 5.1 |
| AML† | |||||||||||
| NR4A1+/−NR4A3−/− | 3 | 23.6 ± 20.5 | 6.33 ± 3.91 | 29.37 ± 18.4 | 235 ± 266 | 23.4 ± 3.2 | 40.3 ± 7.6 | 2.1 ± 0.4 | 2.9 ± 0.4 | 0.2 ± 0.2 | 31.0 ± 7.4 |
| NR4A1−/−NR4A3+/− | 2 | 8.05 ± 1.18 | 6.50 ± 1.70 | 22.80 ± 4.20 | 114 ± 32.6 | 15.2 ± 1.4 | 48.9 ± 7.1 | 1.9 ± 0.6 | 3.6 ± 1.3 | 0.3 ± 0.3 | 30.1 ± 5.3 |
Values are reported as mean ± SD. WBCs indicates white blood cells; and RBCs, red blood cells.
Mice were classified as MDS/MPN or AML based on the Bethesda criteria. In addition to abnormal blood counts, MDS/MPN mice had elevated blasts (but < 20%) in their bone marrow and spleen, and dysplastic granulocytes were present in the peripheral blood, bone marrow, and spleen. MDS/MPN mice also displayed splenomegaly and myeloid cell infiltration into spleen, liver, and lung.
AML mice had > 20% blasts in their peripheral blood and bone marrow and also displayed splenomegaly and myeloid cell infiltration into spleen, liver, and lung.